Using the ObR antagonists Aca-1 and Allo-aca Otvos et al. [15, 28] demonstrated that the leptin-stimulated proliferation of MCF-7 and MDA-MB-231 breast cancer cells (receptively) can be inhibited in a dose-dependent manner. This evidence concerns the gene LEPR and breast cancer.